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ABSTRACT 
The recent paradigm shift towards the use of the kinetics parameters in place of thermodynamic 
constants is leading the computational chemistry community to develop methods for studying the 
mechanisms of drug binding and unbinding. From this standpoint, molecular dynamics (MD) plays 
an important role, in delivering insight at the molecular scale. However, a known limitation of MD 
is that the time scales are usually far from those involved in ligand-receptor unbinding events. 
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Here we show that the algorithm behind supervised MD (SuMD) can simulate the dissociation 
mechanism of drug-like small molecules while avoiding the input of any energy bias to facilitate 
the transition. SuMD was tested on seven different intermolecular complexes, covering four G 
protein-coupled receptors (GPCRs): the A2A and A1 adenosine receptors, the orexin 2 and the 
muscarinic 2 receptors, and the soluble globular enzyme epoxide hydrolase. SuMD well-described 
the multistep nature of ligand-receptor dissociation, rationalized previous experimental data and 
produced valuable working hypotheses for structure-kinetics relationships (SKR).  
INTRODUCTION 
Living organisms are open systems and are therefore characterized by absorption, distribution, 
metabolism and elimination (ADME) phenomena. It follows that the tissue concentration of drugs 
in proximity to their biological targets is subject to continual variations that do not always justify 
the use of thermodynamics binding constants (i.e. the dissociation constant KD - is measured in 
non-physiological, steady-state conditions) to quantify activities, and drive further drug 
developments. In this scenario, the concept of binding kinetics is gaining importance1–3, as the 
dynamic aspect of chemical equilibria relates the KD with the kinetics constants of formation (kon) 
and dissociation (koff) for any noncovalent intermolecular complex: 
𝐾𝐷 =
𝑘𝑜𝑓𝑓
𝑘𝑜𝑛
  (1) 
Notably, while the drug-receptor binding has a stochastic component that relies on the ligand 
concentration (influences the ligand  probability to be in the proximity of the target), the 
dissociation is driven only by the free energy required to break the interactions with the receptor, 
trigger conformational changes, or re-solvate the system. Recently, the residence time (RT - the 
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reciprocal of the kinetic unbinding constant koff) has been successfully employed in drug discovery 
campaigns, as can well correlate with drugs activity4–7. However, in spite of the scientific 
community’s efforts in developing robust structure-kinetic relationships (SKRs)1, the success in 
using kinetics parameters has been so far limited by the high degree of system-dependency. Indeed, 
medicinal chemistry strategies to tune the kinetics of a chemical series on one particular biological 
target may be unsuccessful when applied to a different scaffold, even if it binds in a similar fashion. 
Any attempt to improve a SKR should be robustly rooted in the mechanistic model of the 
association/dissociation events implicated and given that X-ray and cryo-EM determinations 
usually deliver insight only from thermodynamically stable complexes, it follows that 
computational (un)binding pathways will become increasingly important.  
Molecular dynamics (MD) represents a state-of-the-art computational tool routinely employed 
for structure-based drug design (SBDD). MD describes the time evolution of biomolecular systems 
by explicitly considering water, ions, and lipids molecules. The intriguing perspective of 
simulating unbinding events, to retrieve mechanistic and energetic insight, is nevertheless limited 
because the majority of drug-like molecules remain bound to their biological target for a duration 
much longer than the MD capability (very small fragments may represent an exception8). Indeed, 
the RT of a molecule, can extend over several hours, while MD is usually limited to the micro -  
milliseconds timescale9. Computational chemists are developing MD protocols able to increase 
the sampling and therefore overcome this limitation. These algorithms can be classified as either 
enhanced or adaptive methods10,11. The former are based on the simulated input of energy in order 
to facilitate the ligand transition from the energy minimum represented by the bound state to the 
unbound solvated configuration, and comprises metadynamics12,13 (in many different 
implementations14–16), steered MD17, accelerated MD18,19, Gaussian-accelerated MD20,21, random 
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accelerated MD22–24, smoothed potential MD25, and replica exchange26,27. One of the strengths of 
the enhanced sampling methods is the possibility to recover the energy surface of the dissociation 
by keeping track of the energy introduced. Weaknesses, on the other hand, can be the strong 
dependency on the user experience and the reliability of the mechanistic details retrieved, as some 
methods introduce atom positional restraints in order to restrain the secondary and ternary 
structures of the receptor25. The adaptive sampling algorithms, instead, do not modify the 
Hamiltonian of the system but favor the sampling of less visited states by performing successive 
short simulations, according to the previous evolution of the system28. The unbinding of the 
fragment benzamidine from the trypsin enzyme29 represents a successful application of these 
approaches. More recent work on drug-like molecules employed the adaptive sampling method 
WExplore to simulate the dissociation and retrieve a quantitative kinetic description of the overall 
event30–32.  
In this work, we applied supervised MD (SuMD33), an adaptive sampling method originally 
designed to speed up the simulation of binding events, to the unbinding of small molecules. SuMD 
was tested on seven different intermolecular complexes (Table 1 and Table S1) involving four G 
protein-coupled receptors (GPCRs), namely the orexin receptor 2 (OX2R), the muscarinic 2 
receptor (M2R), the adenosine receptors A1 (A1R) and A2A (A2AR), and the cytosolic enzyme 
epoxide hydrolase (sEH). The GPCRs are a superfamily of membrane receptors34 and represent 
the most clinically relevant target of commercialized drugs35. To the best of our knowledge, this 
is the first reported unbiased MD method successfully applied to the unbinding of drug-like 
molecules from these fundamental pharmacological targets36,37. SuMD outcomes were critically 
compared to the biased metadynamics method, highlighting the usefulness of the approach for the 
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mechanistic description of unbinding events, rather than for quantitative estimations of kinetics 
parameters. 
 
METHODS 
The supervised MD (SuMD) protocol for the unbinding 
The supervised MD (SuMD) approach is an adaptive sampling method11 so far employed for 
simulating the formation of intermolecular complexes in timescales that are one or two orders of 
magnitudes faster than the corresponding classic (unsupervised) simulations33. Sampling is gained 
without the introduction of any energetic bias, by applying a tabu–like algorithm to monitor the 
distance between the centers of mass (or the geometrical centers) of the ligand and the predicted 
binding site. A series of short unbiased MD simulations are performed, and after each simulation 
the distances (collected at regular time intervals) are fitted to a linear function. If the resulting 
slope is negative (showing progress towards the target) the next simulation step starts from the last 
set of coordinates and velocities produced, otherwise the simulation is restarted by randomly 
assigning the atomic velocities. The SuMD has been successfully applied to study the binding 
mechanism of both small molecules and peptides33,38–44.  
Here we present a slightly modified version of the SuMD protocol that aims to simulate the 
unbinding of small molecules. As for the original binding version of the protocol, this is realized 
by supervising the inter-centroid distance and considering a short MD simulation as productive if 
at least one of the following criteria is realized: 
 The slope of the fitted linear function has value ≥ 0  
 6 
 The centroids distance at the end of the MD run has increased compared to the last 
productive short MD simulation 
Differently from the original SuMD algorithm, the length (t) of the short simulations performed 
increases along the unbinding pathway, according to the formula: 
∆𝑡 = ∆𝑡0𝑁𝑡𝑖 (2) 
t0 is the duration of the very first MD time window and Nti represents a factor that is picked from 
three user-defined values (Nt1, Nt2, and Nt3), according to the last ligand-protein distance detected. 
Three distance threshold values (D1, D2 and D3 - Table S2) are set and the ligand-protein distance 
(rL) at the end of each MD run is compared to these threshold values, allowing a decision on the 
value of Nti factor according to the following conditions: 
𝑟𝐿  ≤  𝐷1  →  𝑁𝑡𝑖 =  1  (3) 
𝐷1  <  𝑟𝐿  ≤  𝐷2 →  𝑁𝑡𝑖 =  𝑁𝑡1 (4) 
𝐷2  <  𝑟𝐿  ≤  𝐷3 →  𝑁𝑡𝑖 =  𝑁𝑡2 (5) 
𝐷3  <   𝑟𝐿 →  𝑁𝑡𝑖 =  𝑁𝑡3  (6) 
The goal of increasing the simulation time window (t in Equation 2) along the unbinding 
pathway is to facilitate the sampling of metastable states, which can otherwise be poorly visited as 
very short SuMD simulation time windows favor the escape from energy minima (the global 
minima is represented by the orthosteric ligand-protein complex). As reported in Table S2, 
different user-defined values have been tested and normally values of 3 Å, 5 Å and 8 Å are 
 7 
appropriate for D1, D2 and D3 respectively. Longer values are used for the orexin 2 and muscarinic 
2 receptors because the ligands sit further form the receptor surface.  
The SuMD unbinding is iterated until no ligand-protein van der Waals contact is detected by 
means of the GetContacts scripts tools (https://getcontacts.github.io). The distance between the 
ligand and the protein centers of masses (Table S3) was computed using PLUMED 245. 
The supervised MD (SuMD) protocol for the adenosine binding to the A1R. 
To simulate the adenosine binding to the A1R (Table S4) the distance between the centroid of the 
agonist and the centroid of the orthosteric residues N2546.55, F171ECL2, T2777.42, and H2787.43 was 
supervised during 500 ns long time windows until it reached a value less than 3 Å. 
Biological targets and ligand force field parameters 
Four G protein-coupled receptors (GPCR) and one cytosolic protein were considered (a total of 
seven complexes - Table 1 and Table S1). The CHARMM3646,47/CGenFF 3.0.148–50 force field 
combination was employed in the molecular dynamics (MD) simulations performed in this work. 
Initial ligand force field, topology and parameter files were obtained from the ParamChem 
webserver48. Adenosine and NECA are already well-parameterized in the CGenFF force filed. 
ZMA parameters were the same as our previous work51. The dihedral terms of TPPU and QNB 
were visually inspected during short MD simulations in water and no further optimization was 
performed. EMPA rotatable bonds associated with a higher ParamChem penalty were optimized 
at the HF/6-31G* level of theory using the Parameterize utility, which is part of the HTMD52 
environment, after fragmentation of the molecule. 
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Table 1. The seven intermolecular complexes considered. The GPCRs are identified by the 
PDB codes 2YDO53 (A2A R in complex with adenosine), 6D9H
54 (A1 R in complex with 
adenosine), 2YDV53 (A2A R in complex with the agonist NECA), 4EIY
55 (A2A R bound to the 
inverse agonist ZMA), 5WQC56 (OX2 R in complex with the antagonist EMPA), and 3UON
57 (M2 
R in complex with QNB). The cytosolic system has PDB code 4OD07 (sEH complexed with the 
inhibitor TPPU). 
Protein PDB code Ligand Ref 
A2A receptor (A2AR) 2YDO adenosine 53 
A1 receptor (A1R) 6D9H adenosine 54 
A2A receptor (A2AR) 2YDV NECA 53 
A2A receptor (A2AR) 4EIY ZMA 55 
Orexin 2 receptor (OX2R) 5WQC EMPA 56 
Muscarinic 2 receptor (M2R) 3UON QNB 57 
Soluble epoxide hydrolase (sEH) 4OD0 TPPU 7 
 
Protein preparation 
The complete A2AR structures (Table 1 and Table S1) were retrieved from the Adenosiland 
database58. The intracellular loop 3 (ICL3) of the A1 R and OX2R was modelled using Modeller 
9.1959, while no attempt was made to rebuild the M2R ICL3. Hydrogen atoms were added by means 
of the pdb2pqr60 and propka61 software (considering a simulated pH of 7.0); the protonation of 
titratable side chains was checked by visual inspection. The resulting five receptors were 
separately inserted in a square 90 Å x 90 Å 1-palmitoyl-2-oleyl-sn-glycerol-3-phosphocholine 
(POPC) bilayer (previously built by using the VMD Membrane Builder plugin 1.1, Membrane 
Plugin, Version 1.1. at: http://www.ks.uiuc.edu/Research/vmd/plugins/membrane/), through an 
insertion method62, along with their co-crystallized ligand (and the water molecules within 5 Å of 
the ligand). The receptor orientation was obtained by superposing the coordinates on the 
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corresponding structure retrieved from the OPM database63. Lipids overlapping the receptor 
transmembrane helical bundle were removed and TIP3P water molecules64 were added to the 
simulation box by means of the VMD Solvate plugin 1.5 (Solvate Plugin, Version 1.5. at 
<http://www.ks.uiuc.edu/Research/vmd/plugins/solvate/). Finally, overall charge neutrality was 
reached by adding Na+/Cl- counter ions up to the final concentration of 0.150 M), using the VMD 
Autoionize plugin 1.3 (Autoionize Plugin, Version 1.3. at 
<http://www.ks.uiuc.edu/Research/vmd/plugins/autoionize/).  
The sodium ion was retained in the allosteric binding site55,65 of the A2AR-ZMA complex
66 and 
the Gi protein  subunit helix H5 (residues 329 to 355) was kept in the intracellular side of the 
A1R, in order to maintain the full-active conformation of the receptor. 
The simulation box for the sEH-TPPU complex was prepared by titrating the protein and 
solvating the system as described above. One of the two domains of sEH was deleted and the 
remaining one renumbered consistently with ref.32.  
Systems equilibration and general MD settings 
The MD engine ACEMD67 was employed for both the equilibration and productive simulations. 
The equilibration of the membrane systems was achieved in isothermal-isobaric conditions (NPT) 
using the Berendsen barostat68 (target pressure 1 atm) and the Langevin thermostat69 (target 
temperature 300 K) with low damping of 1 ps-1. A four-stage procedure was performed (integration 
time step of 2 fs): first, clashes between protein and lipid atoms were reduced through 2000 
conjugate-gradient minimization steps, then a 2 ns long MD simulation was run with a positional 
constraint of 1 kcal mol-1 Å-2 on protein and lipid phosphorus atoms. During the second stage, 20 
ns of MD simulation were performed constraining only the protein atoms, while in the last 
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equilibration stage, positional constraints were applied only to the protein backbone alpha carbons, 
for a further 20 ns. Globular protein equilibration was achieved in two steps: after 500 cycles of 
conjugate-gradient minimization, the system was simulated for 5 ns, employing an integration time 
step of 2 fs, in the isothermal-isobaric conditions (NPT). 
Productive trajectories (Table S4) were computed with an integration time step of 4 fs in the 
canonical ensemble (NVT). The target temperature was set at 300 K, using a thermostat damping 
of 0.1 ps-1; the M-SHAKE algorithm70,71 was employed to constrain the bond lengths involving 
hydrogen atoms. The cut-off distance for electrostatic interactions was set at 9 Å, with a switching 
function applied beyond 7.5 Å. Long range Coulomb interactions were handled using the particle 
mesh Ewald summation method (PME)72 by setting the mesh spacing to 1.0 Å. 
Metadynamics simulations 
Metadynamics was performed on five out of seven complexes (Table S4). During metadynamics 
simulations a history–dependent energetic is virtually deposited along a predefined set of 
collective variables (CVs) that are able to describe the evolution of the system away from an 
energetic minimum. When this energetic biasing term is added, the probability that the system will 
revisit that specific configuration is decreased according to the shape of the supplied energetic 
Gaussian function. In this way it is possible to computationally fill energy minimum on the energy 
surface that is defined by the CVs, increasing the transition probability between different energy 
minima12,13. Before performing a metadynamics simulation it is necessary to define one or more 
CVs able to describe the system transition of interest. Here, the Gaussian deposition was performed 
along the distances between the geometrical centers of the ligand and the protein (or a part of it - 
Table S3). The use of a similar ligand-receptor distance as CV during unbinding simulations has 
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been successfully applied73 to class A GPCRs. We employed the well-tempered14 version of 
metadynamics: the starting height of the Gaussian energy terms was set at 0.01 kcal mol-1, while 
the width was 0.1 Å, with depositions done every 2 ps using Plumed 245 as an ACEMD67 plugin. 
The bias factor was set to 15 and the temperature to 300 K. The energy surfaces obtained by 
integrating the Gaussians deposited are reported in Figure S1.  
Notably, the metadynamics simulations were not designed to fully reconstruct the unbinding 
energy surfaces (no convergence was reached during the three replicas performed - Figure S1), but 
to supply mechanistic insight for a direct comparison with SuMD. 
Analysis of the MD trajectories 
Interatomic contacts and root mean square deviations (RMSD) were computed using VMD74. A 
contact was considered productive if the distance between two atoms was less than 3.5 Å. Ligand-
protein hydrogen bonds were detected using the GetContacts scripts tool 
(https://getcontacts.github.io), setting a hydrogen bond donor-acceptor distance of 3.3 Å and an 
angle value of 150° as geometrical cut-offs. Contacts and hydrogen bond persistency are quantified 
as the percentage of frames (over all the frames obtained by merging the different replicas) in 
which protein residues formed contacts or hydrogen bonds with the ligand. The computation takes 
into account direct and water mediated interactions.  
Distances between atoms were computed using PLUMED 245. Both the molecular mechanics 
Poisson-Boltzmann surface area (MM/PBSA) energy of the GPCR complexes (implicitly 
modelling the membrane using an heterogeneous dielectric constant) and the molecular mechanics 
energies combined with the generalized Born and surface area continuum solvation (MM/GBSA 
- for the sEH:TPPU complex) method were computed with the MMPBSA.py75 script 
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(AmberTools17 suite at http://ambermd.org/), using the default settings, after transforming the 
CHARMM psf topology files to an Amber prmtop format using ParmEd (documentation. at 
<http://parmed.github.io/ParmEd/html/index.html). We chose to compute the MM/PBSA and 
MM/GBSA energy also on the metadynamics trajectories to allow a direct comparison with the 
unbiased SuMD simulations. Detection of hydrated spots within the binding sites was performed 
on a 100 ns long classic MD simulations by means of AquaMMapS51. 
Numbering system 
Throughout the manuscript, the Ballesteros-Weinstein residues numbering system for the 
GPCRs76 is adopted. 
 
RESULTS 
The A2AR – adenosine complex 
The A2AR is a potential pharmaceutical target for the Parkinson’s disease77–79 and numerous 
cancers80. It is also one of the most characterized GPCRs as, to date, more than 40 X-ray and cryo-
EM structures have been published81. In the bound state53,82 (Figure 1a) the adenosine forms key 
hydrogen bonds with A2AR residues N253
6.55, S2777.42, H2787.43, a water mediated interactions 
with H2506.52,  and a π-π interaction that involves F168ECL2. Moreover, in our simulations it forms 
a water-mediated interaction between the ribose ring and N1815.42, but a direct hydrogen bond can 
occur. 
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Besides the orthosteric residues (Table S5, Table S6), during SuMD unbinding simulations 
(Video S1, Figure 1b) the A2AR side chains I66
2.64, S672.65, I662.64, Y91.35, Y2717.36, L2677.32, 
V172ECL2, L167ECL2, S61.32, A813.29 T2566.58, H264ECL3 and E131.39 engaged in direct interactions 
with adenosine (Table S5, Table S6). E169ECL2 stabilized the ligand with hydrogen bonds and 
water-mediated interactions both in the bound state and throughout the dissociation. Interestingly, 
several SuMD replicas required the E169ECL2 - H264ECL3 salt bridge opening (Video S1 - in line 
with previously reported adenosine binding simulations39) but this does not appear to be a 
fundamental step of the dissociation event. While the key hydrogen bond between adenosine and 
N2536.55 tended to form and break several times before the dissociations started, the almost 
simultaneous rupture of the buried hydrogen bonds formed with S2777.42, H2787.43, and N1815.42 
appears to be the bottleneck of the unbinding (Video S1). In order to break these interactions, water 
molecules coming from the extracellular environment had first to hydrate either the solvent-
exposed hydrogen bond with N2536.55 or the adenine scaffold (Figure S2). Water molecules 
involved came also from a hydrated region located in proximity to the ribose moiety and the 
N1815.42, and H2506.52 side chains (Figure S2), or from within the transmembrane (TM) domain, 
in line with the water flux highlighted in the work from Lee et al. 83. 
The above interaction pattern generally matches with the metadynamics results (Table S5, 
Table S6), but a direct comparison between the two methods shows that under the parameters used 
for these simulations, SuMD sampled more contacts at the extracellular vestibule of A2AR 
(Y2717.36, Y91.35, E131.39, E169ECL2) than the metadynamics, which instead extensively explored 
interactions in the orthosteric site (Figure S3a,b). This is consistent with the points’ distribution in 
the energy landscapes, as the metadynamics sampled more adenosine bound states (spread points 
at minima B Figure S3c) than SuMD did (narrow distribution of point at minima B Figure 1c). 
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Interestingly, while both methods simulated a common unbinding path (Figure 1d, Figure S3d) 
close to the extracellular loop 3 (ECL3), only SuMD explored an alternative route between the 
extracellular loop 2 (ECL2) and the top of transmembrane helix 1 (TM1) (Figure 1d). 
 
Figure 1. The adenosine unbinding from the A2A and A1 receptors. a) The A2AR - adenosine 
X-ray intermolecular complex53. Water oxygen atoms within 3 Å from the ligand are shown in 
red. Hydrogen bonds are highlighted as dashed lines and hydrophobic interactions as a cyan 
transparent surface. The upper portion of TM7 has been removed for clarity. The 2D structure of 
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adenosine is reported in the box. b) A2A R - adenosine (left panel) and A1R - adenosine (right 
panel) unbinding configurations according to SuMD (the adenosine is shown every 1 ns of 
simulation as stick representation). c) A2AR - adenosine unbinding energy landscape from SuMD 
simulations. d) adenosine centroids positions during SuMD, colored according to the energy 
interaction (MMPBSA energy < 0); the A2A R is shown as ribbon and colored according to the 
overall contacts computed during SuMD simulations. e) A1R - adenosine unbinding energy 
landscape from SuMD simulations. f) adenosine centroids positions during SuMD colored 
according to the energy interaction (MMPBSA energy < 0); the A1R is shown as ribbon and 
colored according to the overall contacts computed during metadynamics simulations.  
 
The A1R – adenosine complex and the comparison with the SuMD binding simulations 
The adenosine A1 receptor (A1R) is involved in ischemic disorders
79 and in the nociceptive 
transmission84. The main orthosteric point mutations between A2AR and A1R are 
S67(A2A)
2.65N70(A1), S277(A2A)
7.42T277(A1), and M270(A2A)
7.35T270(A1) 
85, the latter 
contributing strongly to the A1/A2A ligand selectivity
54,86.   
According to SuMD (Figure 1e, f, Video S2, Table S7 and Table S8), the S67(A2A)
2.65N70(A1) 
mutation putatively modifies  the energy landscape of the adenosine unbinding (Figure 1c, e) 
generating a further energy minimum (M1 in Figure 1e) a few Angstroms from the bound state (B 
in Figure 1c, e). Indeed, in contrast to the A2AR, the ligand was forced to overcome transition 
configurations (T1 in Figure 1e) located between the bound state and the metastable state M1, 
where the adenosine hydrogen bonded with N702.64 and N2546.55 side chains and formed 
hydrophobic contacts with F171ECL2 (Figure S4). At ECL3, the H264(A2A)
ECL3K265(A1) mutation 
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potentially modifies the strength of the ionic interaction with E172ECL2 (E169ECL2 in A2A), and 
possibly favored the adenosine unbinding towards the ECL3 path in A1R (Figure 1f) as a 
consequence of the narrower extracellular vestibule conformation. 
We performed SuMD binding simulations (Video S3) to deliver insight from the possible 
differences between the adenosine – A1R association and dissociation pathways (Figure S5). The 
binding routes sampled converged to a metastable site located at the top of TM5, TM5, the distal 
part of ECL2 and the proximal segment of ECL3. After stopping at this intermediate position, 
adenosine formed the orthosteric complex either passing between the E172ECL2 – K265ECl3 salt 
bridge during three replicas out of nine. This produced an energy landscape of the event 
characterized with two intermediate stable states (MA and MB in Figure S5a, b) characterized by 
stability comparable to the final one (state B in Figure S5a, b). Of note, the SuMD binding 
simulations were not combined with classic unsupervised MD to favor the sampling of the 
experimental binding pose33 as we were interested in the non-equilibrium transition from the bulk 
solvent to the final binding site rather that reproducing the well-known final bound state. It is 
highly probable that the cryo-EM adenosine conformation would have produced a deeper energy 
minimum then state B did, justifying the spontaneous orthosteric binding of the ligand.  
Interestingly, the adenosine binding and unbinding routes did not overlap (Figure S5c). This 
indicates a scenario that is not compliant with the principle of microscopic reversibility of binding. 
Such non-compliance has been proposed for process in physiological non-equilibrium conditions 
like binding and protein folding 87,88. 
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The A2AR – NECA complex 
NECA is an adenosine synthetic analogue that bears an ethylcarboxamido moiety on the ribose 5’-
oxydril group (Figure 2). This chemical modification brings the affinity for the A2AR from the high 
to the low-nanomolar range, due to the introduction of two further hydrogen bonds (with T883.36 
and H2506.52 - Figure 2a, Table S9, Table S10) and the displacement of the water molecule that in 
the adenosine X-ray complex is placed in the proximity of N1815.42 and H2506.52  89. All the other 
orthosteric interactions characterizing the endogenous agonist are retained (Figure 2a, Table S9, 
Table S10).  
In contrast to the adenosine simulations, NECA SuMD (Video S4, Figure 2) was more prone 
to sample interactions in the orthosteric site than the metadynamics, with the latter more able to 
explore contacts, hydrogen bonds and water-mediated interactions at the extracellular vestibule of 
the receptor (Figure S6a, b). The NECA propensity to remain in the binding site was driven by the 
direct hydrogen bond between the ligand ethylcarboxamido group and T883.36 (Table S9, Table 
S10, and Figure S7). The rupture of this key interaction represented the bottleneck during the 
dissociation, as it occurred after the break of all the other hydrogen bonds (Figure S7) involving 
the ligand (e.g. the interactions with N2536.55, E169ECL2, S2777.42, H2506.52 and H2787.43) in all the 
SuMD replicas performed (Video S4). The effect of the NECA - T883.36 hydrogen bond is evident 
also on the energy landscape of the unbinding (Figure 2c). The highly populated bound states (B 
in Figure 2c) are indeed markedly separated from the other states along the unbinding path by the 
poorly sampled state T1 (Figure 2c). Notably, there is no evident indication of this T883.36-related 
mechanistic step during metadynamics simulations (Figure S6c, Figure S7). The dynamics of the 
water molecules in the binding site suggests a shielding effect of the T883.36 methyl, which protects 
the T88 hydrogen bond from hydration and therefore increases its persistency (Figure S8). This 
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scenario is in line with the proposed effect that buried hydrogen bonds may have on the overall 
kinetics of unbinding90. Interestingly, the T883.36S mutation dramatically decreases NECA affinity 
for the A2AR
91, suggesting a marked increase in the kinetic of dissociation90 (assuming the 
association rate kon not affected). 
Focusing on the rest of the unbinding paths, both during SuMD and metadynamics simulations 
NECA was able to reach the fully solvated state by transiently interacting with ECL3 (Figure 2d 
and Figure S6d). Subtle differences between the two methods are apparent at ECL2, where NECA 
made more metastable contacts with residues located at the helix portion of the loop according to 
the metadynamics (Figure S6d). 
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Figure 2. NECA unbinding from the A2A receptor. a) The A2AR - NECA X-ray intermolecular 
complex53. Water oxygen atoms within 3 Å from the ligand are shown in red. Hydrogen bonds are 
highlighted as dashed lines and hydrophobic interactions as a cyan transparent surface. The upper 
portion of TM7 has been removed for clarity. The 2D structure of adenosine is reported in the box. 
b) A2AR - NECA unbinding configurations according to SuMD (NECA is shown every 1 ns of 
simulation as stick representation). c) A2AR - NECA unbinding energy landscape from SuMD 
simulations. d) NECA centroids positions during SuMD, colored according to the energy 
interaction reported in panel 2c (MMPBSA energy < 0); the A2AR is shown as ribbon and colored 
according to the overall contacts computed during SuMD simulations.  
 
The A2AR – ZMA complex 
ZMA is considered a prototypical A2AR inverse agonist
92. In the bound state (Figure 3a) the 
triazole-triazine bicyclic scaffold engages N2536.55 and E169ECL2 side chains via hydrogen bonds 
and makes hydrophobic contact with F168ECL2, L2496.51, H2506.52, M2707.35 and I2747.39 (Figure 
3a, Table S11, Table S12). The phenolic group, instead, orients towards the extracellular 
environment (but an alternative conformation interacting with the Y2717.36 side chain has been 
reported93). The structural feature responsible of ZMA antagonistic activity is the absence of the 
ribose ring (characterizing the AR full agonists), as no interaction with the receptor key residues 
S2772.47 and H2782.48 is possible in the complex.  
During SuMD unbinding simulations (Figure 3, Video S5), the antagonist made more 
interactions with the extracellular vestibule of the A2A R than the adenosine and NECA (Figure 
S9a, b). More precisely, the phenolic ring engaged residues located at the top of TM2 (S672.65), 
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TM7 (L2677.32), and L167ECL2 (Figure 3e), while the triazole-triazine scaffold was mainly 
responsible for interactions with ECL2 (E169ECL2, S156ECL2, Q157ECL2, and K153ECL2). In analogy 
with the work of Guo et al.23, ZMA engaged the S156ECL2 and Q157ECL2 side chains (Table S11, 
Table S12, Figure S11a,b) with intermediate hydrogen bonds. Interestingly, the S156AECL2 and 
Q157AECL2 mutations do not affect the unbinding kinetics23, indicating that the transition state of 
the event may occurs earlier. The T256A6.58 and L267A7.32 mutations, on the other hand, strongly 
influence the unbinding kinetics of this ligand23. Regarding the L267A7.32 mutant, a conformation 
of the ethylphenol group alternative to the one observed with L2677.32 has been proposed as a 
determinant for the residence time (RT) increase. The T2566.58, H264ECL3 and E169ECL2 side chains 
are at the edge of a volume occupied by water molecules with low dynamicity, according to the 
AquaMMapS analysis51 (Figure S10). In this scenario, the T256A mutation may destabilize the 
H264ECL3 - E169ECL2 salt bridge, important for the unbinding kinetics of A2AR antagonists
94, 
thereby triggering a decrease of RT (during SuMD simulations, ZMA dissociations occurred when 
the salt bridge was open). The opening of the salt bridge could also influence the key hydrogen 
bonds between N2536.55 and the antagonists (Figure S10), as the water molecule influx from the 
extracellular environment may favor its rupture. 
Comparing the dissociation mechanisms obtained from SuMD and metadynamics, relevant 
differences can be observed at the extracellular vestibule of the receptor (Figure S11a,b), where 
ZMA engaged residues located at the ECL2 helix (S156ECL2, Q157ECL2, and K153ECL2) in 
metastable interactions (states MECL2 in Figure 3c, d) according to SuMD. During metadynamics, 
on the other hand, ZMA was more prone to sample intermediate states in the orthosteric site (as 
indicated by the wide distribution of points in Figure S11c and usually left the binding site by 
ECL3, or through a narrow path in the proximity of the central segment of ECL2 (Figure S11d). 
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The SuMD energy landscape (Figure 3c) highlights a clear discontinuity (T1 in Figure 3c) between 
the orthosteric bound states (B in Figure 3c) and the successive metastable states (MECL2 in Figure 
3c), due to the almost simultaneous break of the polar interactions with N2536.55 and E169ECL2 side 
chains (Video S5). 
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Figure 3. ZMA unbinding from the A2A receptor. a) The A2AR - ZMA X-ray intermolecular 
complex55. Water oxygen atoms within 3 Å from the ligand are shown in red. Hydrogen bonds are 
highlighted as dashed lines and hydrophobic interactions as a cyan transparent surface. The upper 
portion of TM7 has been removed for clarity. The 2D structure of ZMA is reported in the box. b) 
A2AR - ZMA unbinding configurations according to SuMD (ZMA is shown every 1 ns of 
simulation as stick representation). c) A2AR - ZMA unbinding energy landscape from SuMD 
simulations. d) ZMA centroids positions during SuMD, colored according to the energy interaction 
reported in panel 3c (MMPBSA energy < 0); the A2AR is shown as ribbon and colored according 
to the overall contacts computed during SuMD simulations e) A2AR - ZMA SuMD contacts map 
colored according to the structural moiety of the ligand involved; in red and orange are shown the 
residues that mainly interacted with the triazole-triazine scaffold, while in blue are highlighted 
residues that mainly made contacts with the phenol group (white surface indicates either the same 
amount of contacts or no interactions at all). 
 
The OX2R – EMPA complex 
Antagonizing the orexin-2 receptor (OX2R) is considered a valuable therapeutic approach for the 
treatment of narcolepsy95. The recent X-ray structure of the OX2R in complex with the antagonist 
EMPA56 has shed light on subtype selectivity and shown that in the bound state (Figure 4a) the 
ligand is not stabilized by direct hydrogen bonds. A water-mediated interaction is formed between 
Q1343.32 and the two nitrogen atoms of each pyridine ring of EMPA, and a further water-mediated 
hydrogen bond is formed between the carbonyl oxygen of the ligand and the H3507.39 side chain. 
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Moreover, EMPA forms numerous van der Waals contacts with T1112.61, V1383.36, F2275.42, 
I3206.51, S3216.52, N3246.55, H3507.39, and Y3547.43. 
SuMD (Figure 4, Video S6) confirmed the low tendency of EMPA to form direct hydrogen 
bonds with the receptor along the unbinding path (except for Q1874.60, which was engaged in 
intermediate states – Table S13, Table S14, Figure S12a, b). Interestingly, ECL2 and the N-
terminal helix of the receptor chaperoned the ligand during the three replicas sampled (Figure 4b, 
Video S6), suggesting an important role in intermediate stabilization of the ligand. Ligand 
solvation has been suggested to contribute strongly to unbinding transition states96 and, possibly, 
the OX2R extracellular vestibule drives EMPA dissociation providing several hydrophobic 
contacts, and therefore gradual hydration before reaching the bulk. SuMD had the tendency to 
sample more metastable states located in proximity to the orthosteric site (Figure S12a, b), while 
during metadynamics simulations EMPA formed more contacts with the extracellular vestibule of 
the OX2R (Figure S12a, b). Outcomes from SuMD (Video S6) indicated an overall EMPA 
unbinding mechanism (Figure S13) according to which the first step of the dissociation is the 
reorientation of the pyridine ring from the TM bundle core towards the top of TM7/ECL3 (step 1 
in Figure S13a). This conformational change leads to transitory interactions with H3507.39 and 
residues located at the top of TM6 (K3276.58 in Figure S13a) and TM7 (F3467.35 in Figure S13a). 
The second step is proposed to be the EMPA transition to the extracellular vestibule of the receptor, 
where it forms several hydrophobic contacts with ECL2 and ECL3 (Figure S13b). During Step 3 
the inhibitor interacts with the N terminal helix and the distal portion of ECL2 (Figure S13c) before 
completely unbinding. The energy surface from SuMD simulations shows a discontinuity (T1 in 
Figure 4c) between the bound state (B in Figure 4c, d) and the metastable states at the ECL2 (MECL2 
in Figure 4c, d), which corresponds to step 2 of the simulated dissociation mechanism. This 
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transition putatively drives the overall kinetics of the event, as EMPA experienced a possibly 
energetic-unfavorable sudden solvation (Figure S14). 
 
Figure 4. EMPA unbinding from the OX2 receptor. a) The OX2R- EMPA X-ray intermolecular 
complex55. Water oxygen atoms within 3 Å from the ligand are shown in red. Hydrogen bonds are 
highlighted as dashed lines and hydrophobic interactions as a cyan transparent surface. The upper 
portion of TM7 has been removed for clarity. The 2D structure of EMPA is reported in the box. 
b) OX2R – EMPA unbinding configurations according to SuMD (EMPA is shown every 1 ns of 
simulation as stick representation). c) OX2R - EMPA unbinding energy landscape from SuMD 
simulations. d) EMPA centroids positions during SuMD, colored according to the energy 
interaction reported in panel 4c (MMPBSA energy < 0); the OX2R is shown as ribbon and colored 
according to the overall contacts computed during SuMD simulations. 
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The M2R – QNB complex 
The five muscarinic receptors (M1-5 R) modulate the effects of the acetylcholine in both the central 
and parasympathetic nervous systems, with possible therapeutic repercussion on schizophrenia, 
Alzheimer’s and Parkinson’s diseases97. However, the development of selective orthosteric drugs 
has been always complicated by the high degree of identity that characterizes the canonical binding 
site for these receptors. The inactive structure of the subtype M2 was first solved through X-ray 
crystallography 57, delivering insights on the complex with the antagonists 3-quinuclidinyl 
benzilate (QNB). QNB binds in a buried pocket that is separated from the extracellular vestibule 
by the aromatic side chains of three tyrosine residues (Y1043.33, Y4036.51, and Y4267.39). A charge-
charge interaction with D1033.32 and a hydrogen bonds with N4046.52 orient the ligand in the 
binding site (Figure 5a), where a set of further hydrophobic contacts with F181ECL2, T1905.42, 
V1113.40, and W4006.48 completes the interaction pattern. The deep position in the receptor TM 
core contributes to its strong binding (KD in the picomolar range) and makes it a challenging test 
case for SuMD.  
Five unbinding simulations were sampled. As a general view, QNB dissociated following a 
straight route between ECL2 and ECL3 (Figure 5b, Video S7, Table S15 and Table S16) but 
experiencing two major metastable states indicated with (M1 and M2 in Figure 5c and d, Figure 
S15 and Figure S16). In M1 the antagonist slightly rotated, reorienting the two phenyl groups 
towards the extracellular vestibule (Figure S15a), and it tended to break the polar interactions with 
D1033.32 and N4046.52. The T1875.39A mutation has been reported as slightly decreasing QNB 
affinity for M2R
98 and possibly indicates that the transition state along the unbinding occurs in the 
proximity of the orthosteric site. Metastable state M2 (Figure S15b) was characterized by 
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electrostatic interaction with the T1875.39 side chain and several hydrophobic contacts with 
residues located at ECL2 and the top of TM6 and TM7.  
Several analogies can be found with the previously reported biased unbinding simulations of 
tiotropium from the M3R subtype
99. Kruse and collaborators indeed, proposed a linear unbinding 
path characterized by two metastable states above the orthosteric site.  
Given the reduced length of the MRs ECL2 and ECL3, which do not protrude towards the solvent 
bulk phase, it is not surprising that the allosteric sites reported so far 100–102 are topologically 
situated over the canonical orthosteric one and are defined by several side chains from the loops 
as well as the top of all the TMD. Among these, W4227.35 has been suggested to populate two 
rotameric conformations, responsible for orienting the indole horizontally (parallel to the 
membrane surface) or vertically (normal to the membrane surface). Four SuMD replicas out of 
five suggest that the planar orientation would favor the unbinding, contributing to the stabilization 
of the outgoing ligand. 
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Figure 5. QNB unbinding from the M2 R. a) The M2R- QNB X-ray intermolecular complex
57. 
Hydrogen bonds are highlighted as dashed lines and hydrophobic interactions as a cyan transparent 
surface. The top of TM1 and TM2 have been removed for clarity. The 2D structure of QNB is 
reported in the box. b) M2R –QNB unbinding configurations according to SuMD (QNB is shown 
every 1 ns of simulation as stick representation). c) M2R – QNB unbinding energy landscape from 
SuMD simulations. d) QNB centroids positions during SuMD, colored according to the energy 
interaction reported in panel 5c (MMPBSA energy < 0); the M2R is shown as ribbon and colored 
according to the overall contacts computed during SuMD simulations. 
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The sEH – TPPU complex 
The soluble epoxide hydrolase (sEH) is a cytosolic enzyme responsible of the hydrolysis of 
epoxyeicosatrienoic acids (EETs) to the corresponding dihydroxyeicosatrienoic acids (DHETs)103. 
Given the anti-inflammatory action of EETs104, pharmaceutical strategies able to inhibit the sEH 
action should be  beneficial in modulating acute inflammatory disorders105. Among the various 
scaffolds designed, the 1,3-disubstituted urea has been so far characterized as the most potent in 
inhibiting sEH106.  
SuMD unbinding replicas (Figure 6, Video S8) were collected using the X-ray crystal structure 
of sEH in complex with the derivative 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)-
urea (TPPU)7. In the active site (Figure 6a), TPPU engages the key residues D105, Y236, and 
Y153 in hydrogen bonds, while hydrophobic contacts are formed with Y37, F157, L178, M189, 
L198 and the trifluoromethoxy group.  
The dissociation of this complex was recently investigated32 by means of the WExplore 
algorithm31, allowing a direct comparison with our proposed method. Both the SuMD (Table S17, 
TableS18, Figure S17a, b, and Video S8) and the metadynamics (Figure S17a, b) highlighted the 
rupture of the hydrogen bond with D105 as the first step of the unbinding (Figure 6b). During this 
preliminary event, the urea carbonyl oxygen of TPPU was involved in a stabilizing hydrogen bond 
network with Y236, Y153 and N154 (M1 in Figure 6d, e, and Video S8). Successively, in analogy 
to the results from of Dickson et al32, the inhibitor experienced two possible dissociation paths 
(Figure 6c, Video S8). Along Path A (Figure 6c, e) the inhibitor was chaperoned by a hydrogen 
bond with Y153 and experienced a rotation necessary to orient the structure towards the molecular 
gate where it sampled transitory metastable states (MA in Figure 6d) interacting with M189, L187, 
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and L178 (Table S17, Table S18). Path B (Figure 6c, e), instead, was mainly characterized by 
intermediate interactions with S247 and M109 (metastable states MB in Figure 6d, e) and did not 
require a major reorientation of the ligand, already appropriately oriented in the bound state. 
 
Figure 6. TPPU unbinding from the sEH enzyme. a) The sEH - TPPU X-ray intermolecular 
complex53. Water oxygen atoms within 3 Å from the ligand are shown in red. Hydrogen bonds are 
highlighted as dashed lines and hydrophobic interactions as a cyan transparent surface. The 2D 
structure of TPPU is reported in the box. b) First step of unbinding, common to both path A and 
path B; c) TPPU unbinding configurations according to four SuMD replicas (the TPUU position 
is shown every 1 ns of simulation); the ligand dissociation takes place through two main paths: 
along path A the inhibitor is stabilized mainly through interactions with M189, while path B is less 
characterized by metastable states, and requires shorter simulations (Video S8). d) sEH - TPPU 
unbinding energy landscape from SuMD simulations. e) TPPU centroid positions during SuMD, 
colored according to the energy interaction reported in panel 6d (MMGBSA energy < 0); the sEH 
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is shown as ribbon and colored according to the overall contacts computed during SuMD 
simulations. 
 
CONCLUSION 
In the present work, the SuMD protocol was applied to simulate the unbiased dissociation of a set 
of small molecules from four GPCRs (the A1R, A2AR, the M2R, and the OX2R) and a globular 
protein (the enzyme sEH). The GPCRs covered all the three conformations so far experimentally 
reported: the inactive (the A2A R – ZMA, the M2R – QNB, and the OX2 R – EMPA complexes), 
the intermediate active (the A2AR – adenosine complex), and the fully active one (the A1 R – 
adenosine complex). The ligands considered are characterized by a residence time (RT) of several 
minutes (more than one hour in the case of ZMA) and include QNB, which is one of the most 
strongly binding GPCR antagonists with a KD in the picomolar range
107. 
As a general view, SuMD and the metadynamics sampled similar unbinding pathways, with the 
ligand usually experiencing more than one possible exit pathway (except for QNB and EMPA, 
which dissociated respectively from the M2R and the OX2R through one main route). The 
mechanisms proposed by the two methods differ in magnitude of the intermolecular contacts, the 
hydrogen bonds and the water-mediated interactions. Further divergences can be spotted in the 
energy landscapes of the dissociation events: SuMD was overall able to better reconstruct the 
multistep nature of the ligand-receptor dissociations by sampling heterogenous metastable states, 
allowing hypotheses regarding the possible kinetic bottlenecks on the unbinding pathway.  
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This was particularly evident in the case of the NECA, whose dissociation from the A2AR was 
strongly driven by the hydrogen bond with T883.36. Notably, the metadynamics protocol here 
employed relayed only on the ligand-receptor distance metric, to permit a direct comparison with 
SuMD. The introduction of a further biased collective variable during metadynamics (decided 
according to a priori knowledge of the biological target considered) could dramatically increase 
the level of details achievable. 
A remarkable aspect of the EMPA-OX2R complex is the absence of direct protein-ligand 
hydrogen bonds. We have reported a proposed unbinding mechanism for EMPA, according to 
which three main steps occur. Even if the ligand translocation from the orthosteric site to the 
extracellular vestibule has been pointed out as the possible bottleneck of the event, the initial 
reorientation of the pyridyl ring (step 1 in Figure 5) allows the water molecules to start solvating 
the complex. Therefore, chemical modification able to restrain the conformational space of this 
substituent may increase the RT on this biological target. 
The TPPU-sEH complex represented an important benchmark for SuMD, as its unbiased 
dissociation was recently simulated by the WExplore algorithm32. Overall, SuMD sampled a 
dissociation mechanism that highly resembled the one obtained from WExplore, as two different 
main unbinding routes were proposed. Unlike WExplore, the SuMD approach in this current 
implementation does not allow for quantitative estimations of kinetics parameters. However, 
recent computational protocols suggest the possibility of rescaling the simulation time to 
kinetically rank similar compounds22,108. A straightforward approach could rely on the evaluation 
of both the total and the productive SuMD simulation time needed for dissociating structurally 
related compounds. SuMD could be also combined with other adaptive sampling methods to obtain 
a thorough sampling of both binding and unbinding, allowing the construction of kinetic Markov 
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state models. Besides, SuMD output may represent suitable references for metadynamics 
simulations based on path collective variable109,110, which are capable to reconstruct the energy 
surface of the transitions. 
In the future, given the immense chemical space and all the ligand-receptor interaction patterns 
possible, the SuMD approach should be tested on an extended number of different systems, 
comprised those whose unbinding is kinetically driven by major conformational rearrangements 
of the protein. Moreover, to facilitate the use of the protocol, future efforts should be addressed to 
simplify the user-defined settings, implementing a linear scaling of the time windows duration 
along the dissociation path. 
According to SuMD and as a general view, the main bottlenecks of the dissociation from the 
class A GPCRs considered here occurred during early stages of the unbinding. This corroborates 
the importance of the stability of the ground state, represented by the bound complex, in 
modulating the energy of the transition states along the pathway and, in turn, the overall kinetics 
and the RT. The two distinct unbinding routes of TPPU, on the other hand, shared a common first 
dissociation step but were then characterized by different putative bottlenecks. Reasonably, these 
two molecular mechanisms can contribute to the overall kinetics with different weights, as one 
could occur faster than the other (i.e. could be kinetically favored). 
In conclusion, the SuMD approach is a useful unbiased tool for computationally describing both 
the binding and the unbinding mechanism of drug-like molecules from important biological 
targets, such as the GPCRs. In light of its simple algorithm, it can be further developed and easily 
incorporated in any computational drug design pipeline to rationalize existing data and to produce 
new working hypothesis on the whole (un)binding process. 
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